On the basis of current evidence derived from hospital-based studies, mostly from North India, the prevalence of psoriasis in adults varies from 0.44 to 2.8%, with a much lower prevalence in children. The peak age at onset in adults is in the third and fourth decade of life, with a slight male preponderance. It is recommended that population-based large epidemiologic studies should be undertaken in different parts of the country for estimating the correct prevalence of psoriasis in general population. Chronic plaque-type psoriasis is the most common morphologic presentation of psoriasis, accounting for more than 90% of all cases. Other morphologic variants that deserve special mention include palmoplantar psoriasis, pustular psoriasis, and recalcitrant psoriasis.For epidemiologic purposes, psoriasis can be classified into early and late onset psoriasis. Psoriasis can be classified on the basis of morphology and extent of involvement into localized and widespread disease.For the purpose of clinical trials, psoriasis may be classified as mild psoriasis, moderate psoriasis, and severe psoriasis. The literature shows that there is a significant risk of psoriatic arthritis (7-48%) in patients with plaque-type psoriasis. Hence, it is recommended to evaluate for its presence by detailed history taking and clinical examination, and if necessary, by appropriate radiological investigations. Evidence on the association between plaque-type psoriasis and cardiovascular disease risk factors and ischemic heart disease isinconsistent.On the basis ofavailable evidence, it is prudent to proactively look for metabolic syndrome, dyslipidemia, and obesity, especially in patientswith severe psoriasis (Level 1+ evidence based on systematic reviews and meta-analysis). Based on the current evidence, the psoriasis area severity index appears to be the most valid and reproducible clinical severity score in the management of adult patients with plaque-type psoriasis.
INTRODUCTION
P s o r i a s i s i s a c h r o n i c i n f l a m m a t o r y immune-mediated proliferative skin disorder that predominantly involves the skin, nails, and joints. Robert Willan, the father of modern dermatology, is credited with the first detailed clinical description of psoriasis, and hence, it is also termedas Willan'slepra. [1] The association between arthritis and psoriasis was described for the first time by Alibert in 1818, and the American Rheumatology Association recognized it as a separate entity in 1964.
Epidemiology
The worldwide prevalence of psoriasis is estimated to be approximately 2-3%. [2] Although the disease is known to have higher prevalence in the polar regions of the world, its burden in a tropical/subtropical country like India cannot be underestimated.In a diverse country such as India, the prevalence of psoriasis may vary from region to region due to variable environmental and genetic factors. We found only six studies, mostly in a hospital setting, from North India estimating the prevalence of disease among adult dermatologic patients [ Table 1 ]. [3] [4] [5] [6] [7] [8] A higher prevalence in males has been reported with a peak age at onset is in the third and fourth decade of life. [9, 10] In one of the larger studies from Northern India, point prevalence of pediatric psoriasis was estimated to be 0.0002%. 6-10 years age group compared to girls in 11-15 years age group. [12] A positive family history may be elicited in 9.8-28% of the children. The age at onset of psoriatic arthritis varies from 35 to 50 years with no sex predilection. Nearly 70% of the patients develop psoriasis before articular involvement; in another 15%, arthritis precedes the onset of psoriasis by more than 1 year, and in the remaining 15% of the cases, the two conditions occur within 12 months of each other. [13] The yearly estimated incidence and prevalence of psoriatic arthritis are, respectively, 3.0-23.1 cases/100,000 and 1-420 cases/100000 people, [14] [15] [16] [17] [18] [19] [20] [21] with similar results in Western countries and in China. Prey et al. in their systematic review of literature concluded that psoriatic arthritis may affect upto 24% of patients with psoriasis. [14] Such data is lacking among Indian patients. In children, arthritis may precede psoriasis in 50% of cases. The mean age of onset in children is 9-10 years with female predominance. [22] 
DEFINITIONS, CLASSIFICATION, AND CLINICAL PRESENTATION

Psoriasis
There is no clear definition or criteria proposed for the diagnosis of psoriasis as the diagnosis is essentially clinical. Based on the current understanding of its pathogenesis, psoriasis can be defined as a papulosquamous disorder characterized by disordered keratinization arising due to T cell-mediated immune dysregulaion. Epidemiologically, psoriasis has been classified into early onset and late onset psoriasis by Henseler and Christophers [ Table 2 ]. [23] Guinot et al. have recently classified psoriasis into six phenotypic types. [24] 
Psoriatic arthritis
Psoriatic arthritis belongs to the broad group of spondyloarthropathies which is characterized by its association with psoriasis and seronegativity for rheumatoid factor. [25] The most accepted classification criteria has been published in 2006 by the Classification Criteria for Psoriatic Arthritis (CASPAR) study group [ Table 2] . [26] CASPAR classification is easy to use enabling psoriatic arthritis to be diagnosed in the presence of rheumatoid factor and absence of psoriasis, provided typical findings of psoriatic arthritis are present. It has high sensitivity in early psoriatic arthritis, and may, therefore, be used to classify patients early in the course of disease. [27] 
Pustular psoriasis
Pustular psoriasisis characterized by appearance of macroscopic sterile pustules in a patient with psoriasis. On the basis of extent of involvement, it can be classified into localized or generalized disease [ Table 2 ].
Chronic plaque-type psoriasis is the most common morphologic variety which manifests as circumscribed, well-demarcated, erythematous plaques involving particularly the extensor aspects of elbows and knees, buttocks, scalp, and lower back. The character of scaling varies from the typical silvery-white scales to waxy yellow or orange-brown scales. Other clinical patterns of psoriasis include guttate psoriasis, unstable psoriasis, hyperkeratotic psoriasis, erythrodermic, and pustularpsoriasis, uncommon variants such asfollicular psoriasis, eczematous psoriasis, flexural psoriasis, nail psoriasis, and photosensitive psoriasis. The Medical Advisory Board of the National Psoriasis Foundation has defined mild, moderate, and severe psoriasis based largely on quality-of-life (QOL) measures, with consideration also given to proportion of body surface area affected [ Table 2 ]. [31] As in adult psoriasis, chronic plaque psoriasis with its variants is the most frequent type in infancy and childhood. Inverse psoriasis is more common in children than inadults. In infants, the disease may manifest as diaper dermatitis. In small children and adolescents, guttate psoriasis is another distinct presentation and has been reported in up to 44% of patients. [35] Pustularpsoriasis, although rare in children, can present with certain typical morphological patterns such as annular and circinate pustular psoriasis. Annular pustular psoriasis is characterized by gyrate lesions with erythema and a collarette of scales at the periphery. Psoriatic erythroderma and psoriatic arthritis are relatively less common. International Psoriasis Contd... Type II psoriasis or late onset psoriasis presents after the age of 40 years, with a distinct peak at 55-60 years. Patients are older and have more stable psoriasis, with no family history. Nail involvement is more common in patients in this group who are HLA-Cw*0602 negative. [28] Classification on basis of morphology, size of lesion and extent [29] Stable/unstable Thin (<0.75 mm)/thick (>0.75 mm)
Small plaque (<3 cm dia)/large plaque(>3 cm dia)
Localized -Flexural/intertriginous, facial/seborrheic, scalp psoriasis, palmoplantar psoriasis (nonpustular), psoriasis on limbs and trunk Widespread -Guttate, generalized pustular, erythrodermic psoriasis
Less common varieties -Nail psoriasis, follicular psoriasis, hyperkeratotic psoriasis, photosensitive psoriasis, verrucous psoriasis
Classification on basis of age of onset, course of disease, extent of lesions, and associations [24] Type 1 -late onset disease, few lesions involving mainly the scalp and elbows, without associated arthritis, atopy or sensitivity to environmental factors, a continuous evolution and without familial psoriasis Type 2 -Late onset disease characterized by palmoplantar psoriasis regardless of the presence of pustules, frequent arthritis and more in smokers, less affected by environmental change, but contact dermatitis common Type 3 -early onset of the disease, more in females, few pruritic nummular plaques present mainly the scalp and elbow, arthritis and atopy are common, ppt factors such as stress, koebner's and seasonal variation are frequent, associated contact dermatitis, and familial history of psoriasis common Type 4 -Severe form involving all body sites, except the soles, palms and nails, not linked to the age of onset, guttate and mixed lesions, less frequent to koebner phenomenon, pruritus, atopy, personal, and familial history of arthritis and smokers
Type 5 -early onset widespread disease, less on the palms and soles, more frequent guttate and mixed lesions, arthritis, precipitating factors, atopy, pruritus, familial psoriasis, and more in smokers and alcoholics Type 6 -characterized by skin lesions involving all body sites including the soles and palms, strongly associated with the metabolic syndrome, pustular exacerbation common, presence of mixed lesions, pruritus, sensitivity to environmental factors, smoking but less frequent atopy Classification on basis of disease severity [30] National Psoriasis Foundation
Mild psoriasis can be defined as a disease which generally involves <5% of body surface area. Disease does not alter the patient's quality of life (QOL) and the treatments have no known serious risks
Moderate psoriasis generally involves 2-20% of the body surface area. In addition, the disease alters the patient's QOL and the therapies used have minimal risks
Severe psoriasis generally involves >10% of body surface area. Disease alters the patient's QOL, does not have a satisfactory response to treatments that have minimal risk, and the patients are willing to accept life-altering sideeffects to achieve less disease or no disease
British Association of Dermatologists defines severe psoriasis as disease with PASI ≥10 and DLQI ≥10 [9] (mild: PASI <3, moderate 3-10)
IADVL SIG Psoriasis: mild disease (PASI/BSA <10), moderate to severe disease (PASI/BSA >10). Patients having localized areas involvement but with significant functional disability or psychosocial morbidities such as severe palmoplantar psoriasis can also be considered for systemic therapy/phototherapy. [32, 33] One percent of BSA is approximately equal to the patient's open hand (from the wrist to the tips of fingers) with fingers tucked together and the thumb tucked to the side, as stated in the Koo-Menter Psoriasis Instrument. [34] In clinical trials, severe disease often is commonly defined as more than 10% affected BSA, and the US FDA has used 20% BSA to indicate severe disease. Council has put forward a new classification thatincludes various clinical phenotypes of psoriasis and may be relevant to clinical practitioners and researchers. [30] 
Psoriatic arthritis: Clinical features
Three different clinical patterns of psoriatic arthritis can be recognized, namely, oligoarticular (≤4 involved joints) or polyarticular (≥5involved joints), peripheral disease, and axial disease with or without peripheral arthritis. Various studies have shown peripheral psoriatic arthritis to be the most frequent pattern with asymmetric knee involvement to be the most common presentation in 40% of the patients. [36] The DIP arthritis has been reported to account for 1-59% of cases in various studies, although it is not very specific for psoriatic arthritis and may be seen in other spondyloarthropathies. It is often associated with dactylitis and nail dystrophy. [37] Variables that predict the severity of disease include polyarticular involvement at the onsetincluseraised erythrocyte sedimentation rate, late onset disease, HLA-B27 positivity for psoriatic arthritis spondylitis, and presence of TNF-α-308 and TNF-β-252 gene polymorphism. [38] Nail involvement occurs in nearly 75% of psoriatic patients with arthritis. Axial psoriatic arthritis is seen in 5-36% of the patients with psoriatic arthritis; axial involvement may be in the form of sacroiliitis or limited to only one tract of the spine with or without concomitant peripheral arthritis. [39] Axial psoriatic arthritis may only affect the cervical spine with sparing of other tracts of the axial skeleton. [40] It is characterized by a better prognosis and minor functional damage compared to ankylosingspondylitis.
Enthesitis represents a hallmark of the clinical spectrum of psoriatic arthritis, and it is usually defined in the presence of tenderness and swelling in an enthesis site. Plantar fasciitis and Achille'senthesitis are very common. Dactylitis or the "sausage-shaped digit"is defined as a diffuse swelling of the entire digit and is seen in 5.6-53% of reported cases. [38, 39] The swelling is believed to be due to a combination of flexor tenosynovitis and interphalangeal joint synovitis. Distal extremity swelling with pitting edema is not infrequently observed in psoriatic arthritis (in nearly 21% patients). When distal edema involves the dorsum of the hand a"boxing glove"appearance is seen.
CO-MORBIDITIES ASSOCIATED WITH PSORIASIS
Psoriasis has been associated with numerous dermatologic and non-dermatologic diseases [ Table 3 ]. [41] [42] [43] [44] [45] [46] In recent years, there has been an enormous interest on the association of psoriasis with conventional cardiovascular risk factors (e.g., metabolic syndrome, obesity, low physical activity, smoking, alcohol, lipid abnormalities, hypertension), nonconventional cardiovascular risk factors such as deranged homocysteine metabolism, cardiovascular comorbidities, and increased risk of myocardial infarction and myocardial infarction. [47, 48] However, the data supporting the occurrence of such an association is not consistent. The prevalence of metabolic syndrome in the developed countries varies from 15 to 35%. [49] Two Indian studies that differed in their definition of obesity reported the prevalence of 13 and 41% in general population. [50, 51] The third Indian study reported a prevalence of 11.2% for metabolic syndrome. [52] In one of the largest and well-conducted meta-analysis, it was concluded that, based on information, mostly from hospital-based studies, psoriasis is associated with cardiovascular disease and its risk factors, and not with cerebrovascular disease. [53] The association is stronger with psoriatic arthritis compared to psoriasis. However, Prey et al. in their systematic review of epidemiologic studies studying the cardiovascular risk factors in chronic plaque psoriasis concluded that there is an increased risk of obesity and metabolic syndrome in psoriasis, although no consistent results were found with hypertension, diabetes, and dyslipidemia. [48] Armstrong et al. in their systematic review alsofound similar results, especially in severe psoriasis. [54] In another recent systematic review and meta-analysis, Samarasekera et al. noted that increased cardiovascular risk was identified only in individuals with severe psoriasis (requiring systemic therapy or hospital admission). [55] They also observed that uncertainty remains about whether cardiovascular risk is directly attributable to psoriasis, as the majority of studies failed to adequately adjust for key traditional risk factors. In the landmark population-based Rotterdam study, the risk of incident cardiovascular disease was not increased in psoriasis. [56] Although, the patient population in this study was younger, smoked more, had higher diastolic blood pressure and body mass index levels compared to controls, there was no significant difference in the adjusted carotid intima-media thickness, crude and adjusted ankle-brachial index, pulse-wave velocity, and coronary artery calcium scores. Table 4 summarizes the results of Indian studies evaluating association between psoriasis and metabolic syndrome. [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] 
CLINICAL SCORES IN PSORIASIS
A variety of scoring systems have been used to assess the severity of plaque-type psoriasis. These include the clinical severity scores and quality of life scores, which are enumerated in Table 5 . The clinical scores incorporate and grade the typical clinical features of psoriasis, i.e., erythema, scaling, infiltration, and extent of body surface area involved. Few scores, such asSPI, also include the psychosocial impact of the disease. Such patients are at an increased risk for methotrexate-induced hepatotoxicity and develop liver fibrosis at a lower cumulative methotrexate dose.
Madanagobalane et al. found the occurrence of NAFLD to be higher in psoriasis patients than in controls (17.4 vs 7.9%; P=0.002). [41] NAFLD patients in the psoriasis group (n=58) were more likely to have diabetes (P=0.02) than those with psoriasis alone (n=254).
Another recent cross-sectional study observed that elderly patients (55 years or older) with psoriasis are 70% more likely to have NAFLD than those without psoriasis independent of common NAFLD risk factors. [42] Genitourinary
Erectile dysfunction occurs more commonly in patients with psoriasis, in part due to incipient atherosclerosis. [43] Gastroinstestinal Prevalence of celiac disease is greater in patients with psoriasis than in controls. [44] Musculoskeletal, excluding psoriatic arthritis
Osteoporosis has been linked to palmoplantar pustular psoriasis particularly in females. [45] Onychopachydermoperiostitis has been rarely reported. It is considered as a subtype of psoriatic arthritis.
Pulmonary
Prevalence of chronic obstructive pulmonary disease is significantly higher in patients with psoriasis, and both are related to metabolic syndrome. [46] Rare association of apical pulmonary fibrosis with psoriatic spondylitis and chronic plaque psoriasis with or without peripheral arthropathy has been reported.
Ocular
Range from blepharitis, meibomian gland dysfunction, chronic nonspecific conjunctivitis, punctuate epithelial keratitis, superficial or deep opacities, stromal infiltrates, neovascularization, erosions, scarring, and even stromal melts. Involvement of uvea, particularly anterior uveitis, has been associated with the arthropathic form of psoriasis.
Corticosteroid therapy and PUVA therapy may predispose to development of cataract.
Psoriatic arthritis clinical course may be complicated by iridocyclitis in 2-25% patients.
Dermatologic associations Psoriasis may be associated with various dermatoses such as bullous pemphigoid, pemphigus, and vitiligo.
Associations with palmoplantarpustulosis
Palmoplantarpustulosis has been associated with autoimmune thyroid disease, type 2 diabetes mellitus.
An association between palmoplantar pustulosis, osteitis, and hyperostosis of the clavicular and costosternal joints in SAPHO syndrome (synovitis-acne-pustulosis-hyperostosis-osteomyelitis syndrome) is well documented.
Miscellaneous systemic diseases
Amyloidosis, IgA nephopathy and aortic valve disease have been rarely described in psoriatic arthritis.
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Contd... Kumar et al. [66] 2016 Case-control study to study the association between psoriasis and metabolic syndrome as per NCEP ATP III with Asian modification for waist circumference.
patients and controls
Prevalence of metabolic syndrome, elevated blood glucose, higher waist circumference, and higher triglyceride levels were more common in psoriatic patients than in controls, however, the difference was statistically insignificant The prevalence of low HDL levels was significantly higher in cases compared to controls (86.7% vs. 60%, P=0.02).
Kothiwala et al. [65] 2016 Cross-sectional study to study the association between psoriasis and metabolic syndrome as per NCEP ATP III criteria.
140 patients and 140 controls. 30 patients and 30 controls were selected for cardiac evaluation.
The prevalence of metabolic syndrome, hypertension, abdominal obesity, and diabetes was significantly more in psoriatic patients than in controls. Patients with psoriasis had significantly higher carotid intima-media thickness (mean 0.61 mm±0.01 mm vs. 0.37 mm±0.01 mm) than controls Sharma et al. [64] 2016 Case-control study to study the association between psoriasis and metabolic syndrome as per NCEP and IDF criteria 100 patients and 100 controls
Metabolic syndrome (38%:12%), hypertriglyceridemia (53%:25%), impaired glucose tolerance (38%:16%) (P<0.001) and low HDL (P=0.002) were significantly more in cases versus controls as were the mean values of triglycerides and fasting blood sugar. Mean age of patients and duration of disease strongly correlated with the presence of metabolic syndrome. IDF and NCER were significantly divergent in their disease definition (P<0.001).
Ali et al. [63] 2014 Case-control study to study the association between psoriasis and metabolic syndrome as per IDF criteria Not mentioned Hypertriglyceridemia (59% vs. 31%), abdominal obesity (45% vs. 39%), and hypertension (39% vs. 34%) were significantly more common in cases, whereas diabetes mellitus (23% vs. 29%) (P>0.05) was more common among the controls.
Sharma et al. [62] Tables 6 and 7 summarize the salient features of these clinical severity scores. All scores except SAPASI are assessed by physicians. Although PASI, BSA, and PGA have been approved by FDA for use in clinical trials, all have certain pitfalls. The most widely used scale is PASI as it is the most extensively validated, however, it lacks sensitivity for mild disease and does not evaluate quality of life impairment and comorbidities. A 75% reduction in the PASI score (PASI 75) is the current benchmark of primary endpoints for most clinical trials of psoriasis. However, Carlin et al. concluded that PASI of 50 equates to a clinically meaningful improvement in psoriasis. They observed that PASI score is not linearly reflective of psoriasis severity and that an improvement in quality of life exists at PASI 50. [68] British Association of Dermatologists defined adequate response to treatment as either attainment of PASI 50 and decrease in ≥5 points in DLQI or attainment of PASI 75. [69] Psoriasis has a significant negative impact on patients' health related quality of life. Lower quality of life in psoriasis patientsis due to its physical symptoms such as pruritus, scaling and joint pains, financial and psychosocial impact leading to problems of self-esteem, stigmatization, feeling of shame and embarrassment, and maladaptive coping responses. Bronsard et al. in their systematic review of quality of life scores in psoriasis identified 21 questionnaires, of which 8 satisfied the validation criteria. [70] The advantages and the shortcomings of each of these scores are summarized in Table 7 . Bronsard et al. concluded that DLQI is the easiest to use in clinical trials due to its brevity and simplicity. 
Authors Study design Number of patients Results
Pereira et al. [58] 2011 Cross-sectional study 77
The prevalence of impaired fasting glucose, impaired glucose tolerance, and diabetes mellitus in psoriasis patients was 5.2, 9.1, and 32.5, respectively, as compared to 6.5, 3.3, and 15.2%, respectively, in the controls. There was no association between psoriasis and dyslipidemia.
Nisa et al. [57] 2010 Case-control study 150 Metabolic syndrome: 28% vs 6%; arterial hypertension: 49.3% vs 16%; hypertriglyceridemia: 48.6% vs 16%; impaired fasting glucose levels: 18% vs 2.6% Table 6 : Salient features of clinical severity scores in psoriasis Score Features PASI Gold standard content validity; good overall internal consistency; good overall intraobserver variation; acceptable overall interobserver variation; acceptable overall sensitivity to change BSA Good overall content validity; good overall intra-observer variation; unacceptable overall inter-observer variation PGA Good overall content validity; good overall intraobserver variation; acceptable overall inter-=observer variation LS-PGA Good overall content validity, good overall internal consistency; good overall intraobserver variation; good overall interobserver variation SPI Good overall content validity; good overall intraobserver variation; acceptable overall interobserver variation SAPASI Acceptable overall content validity; good overall intraobserver variation; good overall interobserver variation; acceptable overall sensitivity to change 
